Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Gastrointestinal 2Tumor-Agnostic 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 1Osteoporosis 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 134pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Letrozole 28Drug Therapy 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23durvalumab 22Albumin-Bound Paclitaxel 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20Specimen Handling 20Filgrastim 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Calcium × Gynecologic × Clear all
NCT00321932 2017-03-09

Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant

University of Minnesota

Phase 2 Completed
61 enrolled 16 charts
GynecologicLymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Osteoporosis, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡